Analysis on the therapeutic effect of Cangfu Daotan Decoction combined with drospirenone and ethinylestradiol tablets (II) on patients with polycystic ovary syndrome
This study was designed to investigate the therapeutic effect of Cangfu Daotan Decoction (CDD) combined with drospirenone and ethinylestradiol tablets (II) on patients with polycystic ovary syndrome (PCOS). Patients with PCOS were gathered from September 2020 to September 2022 and divided into the e...
Gespeichert in:
| Veröffentlicht in: | Prostaglandins & other lipid mediators 2024-02, Vol.170, p.106801-106801, Article 106801 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 106801 |
|---|---|
| container_issue | |
| container_start_page | 106801 |
| container_title | Prostaglandins & other lipid mediators |
| container_volume | 170 |
| creator | Fu, Yanhong Xie, Pengpeng Yang, Qingping Chen, Peng Yu, Jingwei |
| description | This study was designed to investigate the therapeutic effect of Cangfu Daotan Decoction (CDD) combined with drospirenone and ethinylestradiol tablets (II) on patients with polycystic ovary syndrome (PCOS).
Patients with PCOS were gathered from September 2020 to September 2022 and divided into the experimental group (n = 36), treated with CDD combined with drospirenone and ethinylestradiol tablets (II), and the control group (n = 41), received only drospirenone and ethinylestradiol tablets (II). Levels of sex hormone, obesity, blood glucose, blood lipid were detected and compared between the two groups pre- and post-treatment. The treatment efficacy, Traditional Chinese Medicine (TCM) syndrome score, adverse drug reactions, and pregnancy rate were compared as well.
After treatment, the experimental group had a higher treatment efficacy (94.44% vs 73.17%, P |
| doi_str_mv | 10.1016/j.prostaglandins.2023.106801 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2892270872</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2892270872</sourcerecordid><originalsourceid>FETCH-LOGICAL-c264t-b86d982266efc85066f851ce11e6bf1b38ede6a20524e53b5f2c5323afe7db683</originalsourceid><addsrcrecordid>eNpVkU1u2zAQhblIkaROr1BwkYW7sMsfi6KAbgK7SQwE6CZZExQ1jGlIpCpSDXSg3rNU7BbogiDAmTfvcT6EbilZU0LF1-O6H0JM-rXVvnE-rhlhPJeEJPQCXVNSyZWUjF-hjzEeCWGEUnKJrnhZyU1Zba7R7zuv2ym6iIPH6QDzGXQPY3IGg7VgEg4Wb7V_tSPe6ZC0xzswwSSXFSZ0tfPQ4DeXDrjJYXo3gA8ecE6EIR2cn1qIadCNCy1Oum4hRbzc77_Mjr1ODnx-eNf3oZ3MFGfr8EsPE46TzzM7uEEfrG4jfDrfC_Ry__15-7h6-vGw3949rQwTm7SqpWgqyZgQYI0siBBWFtQApSBqS2suoQGhGSnYBgpeF5aZgjOuLZRNLSRfoOVpbl7rzzHHVp2LBtq8XghjVExWjJVEliy3fju1mvzpOIBV_eC6HFpRomY46qj-h6NmOOoEJ8s_n53GuoPmn_gvGf4HkpGXmA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2892270872</pqid></control><display><type>article</type><title>Analysis on the therapeutic effect of Cangfu Daotan Decoction combined with drospirenone and ethinylestradiol tablets (II) on patients with polycystic ovary syndrome</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Fu, Yanhong ; Xie, Pengpeng ; Yang, Qingping ; Chen, Peng ; Yu, Jingwei</creator><creatorcontrib>Fu, Yanhong ; Xie, Pengpeng ; Yang, Qingping ; Chen, Peng ; Yu, Jingwei</creatorcontrib><description>This study was designed to investigate the therapeutic effect of Cangfu Daotan Decoction (CDD) combined with drospirenone and ethinylestradiol tablets (II) on patients with polycystic ovary syndrome (PCOS).
Patients with PCOS were gathered from September 2020 to September 2022 and divided into the experimental group (n = 36), treated with CDD combined with drospirenone and ethinylestradiol tablets (II), and the control group (n = 41), received only drospirenone and ethinylestradiol tablets (II). Levels of sex hormone, obesity, blood glucose, blood lipid were detected and compared between the two groups pre- and post-treatment. The treatment efficacy, Traditional Chinese Medicine (TCM) syndrome score, adverse drug reactions, and pregnancy rate were compared as well.
After treatment, the experimental group had a higher treatment efficacy (94.44% vs 73.17%, P < 0.05) and a higher pregnancy rate (44.44% vs 21.95%, P < 0.05) than the control group, but the difference in the incidence of adverse drug reactions was not statistically significant (P > 0.05). Compared with control group, TCM syndrome score and levels of fasting blood glucose, fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR), and waist circumference of the experimental group after treatment displayed remarkable reduction (P < 0.05), while the levels of estradiol (E2) and high-density lipoprotein cholesterol (HDL-C) showed a remarkable increase (P < 0.05).
CDD in combination with drospirenone and ethinylestradiol tablets (II) may be effective in treating PCOS by improving obesity, glucose metabolism and lipid metabolism with no serious adverse events, making it a feasible clinical practice option.</description><identifier>ISSN: 1098-8823</identifier><identifier>DOI: 10.1016/j.prostaglandins.2023.106801</identifier><identifier>PMID: 37984794</identifier><language>eng</language><publisher>United States</publisher><subject>Androstenes ; Drugs, Chinese Herbal ; Female ; Humans ; Insulin Resistance ; Obesity ; Polycystic Ovary Syndrome - drug therapy ; Polycystic Ovary Syndrome - metabolism ; Pregnancy ; Tablets - therapeutic use</subject><ispartof>Prostaglandins & other lipid mediators, 2024-02, Vol.170, p.106801-106801, Article 106801</ispartof><rights>Copyright © 2023 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c264t-b86d982266efc85066f851ce11e6bf1b38ede6a20524e53b5f2c5323afe7db683</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37984794$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fu, Yanhong</creatorcontrib><creatorcontrib>Xie, Pengpeng</creatorcontrib><creatorcontrib>Yang, Qingping</creatorcontrib><creatorcontrib>Chen, Peng</creatorcontrib><creatorcontrib>Yu, Jingwei</creatorcontrib><title>Analysis on the therapeutic effect of Cangfu Daotan Decoction combined with drospirenone and ethinylestradiol tablets (II) on patients with polycystic ovary syndrome</title><title>Prostaglandins & other lipid mediators</title><addtitle>Prostaglandins Other Lipid Mediat</addtitle><description>This study was designed to investigate the therapeutic effect of Cangfu Daotan Decoction (CDD) combined with drospirenone and ethinylestradiol tablets (II) on patients with polycystic ovary syndrome (PCOS).
Patients with PCOS were gathered from September 2020 to September 2022 and divided into the experimental group (n = 36), treated with CDD combined with drospirenone and ethinylestradiol tablets (II), and the control group (n = 41), received only drospirenone and ethinylestradiol tablets (II). Levels of sex hormone, obesity, blood glucose, blood lipid were detected and compared between the two groups pre- and post-treatment. The treatment efficacy, Traditional Chinese Medicine (TCM) syndrome score, adverse drug reactions, and pregnancy rate were compared as well.
After treatment, the experimental group had a higher treatment efficacy (94.44% vs 73.17%, P < 0.05) and a higher pregnancy rate (44.44% vs 21.95%, P < 0.05) than the control group, but the difference in the incidence of adverse drug reactions was not statistically significant (P > 0.05). Compared with control group, TCM syndrome score and levels of fasting blood glucose, fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR), and waist circumference of the experimental group after treatment displayed remarkable reduction (P < 0.05), while the levels of estradiol (E2) and high-density lipoprotein cholesterol (HDL-C) showed a remarkable increase (P < 0.05).
CDD in combination with drospirenone and ethinylestradiol tablets (II) may be effective in treating PCOS by improving obesity, glucose metabolism and lipid metabolism with no serious adverse events, making it a feasible clinical practice option.</description><subject>Androstenes</subject><subject>Drugs, Chinese Herbal</subject><subject>Female</subject><subject>Humans</subject><subject>Insulin Resistance</subject><subject>Obesity</subject><subject>Polycystic Ovary Syndrome - drug therapy</subject><subject>Polycystic Ovary Syndrome - metabolism</subject><subject>Pregnancy</subject><subject>Tablets - therapeutic use</subject><issn>1098-8823</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkU1u2zAQhblIkaROr1BwkYW7sMsfi6KAbgK7SQwE6CZZExQ1jGlIpCpSDXSg3rNU7BbogiDAmTfvcT6EbilZU0LF1-O6H0JM-rXVvnE-rhlhPJeEJPQCXVNSyZWUjF-hjzEeCWGEUnKJrnhZyU1Zba7R7zuv2ym6iIPH6QDzGXQPY3IGg7VgEg4Wb7V_tSPe6ZC0xzswwSSXFSZ0tfPQ4DeXDrjJYXo3gA8ecE6EIR2cn1qIadCNCy1Oum4hRbzc77_Mjr1ODnx-eNf3oZ3MFGfr8EsPE46TzzM7uEEfrG4jfDrfC_Ry__15-7h6-vGw3949rQwTm7SqpWgqyZgQYI0siBBWFtQApSBqS2suoQGhGSnYBgpeF5aZgjOuLZRNLSRfoOVpbl7rzzHHVp2LBtq8XghjVExWjJVEliy3fju1mvzpOIBV_eC6HFpRomY46qj-h6NmOOoEJ8s_n53GuoPmn_gvGf4HkpGXmA</recordid><startdate>202402</startdate><enddate>202402</enddate><creator>Fu, Yanhong</creator><creator>Xie, Pengpeng</creator><creator>Yang, Qingping</creator><creator>Chen, Peng</creator><creator>Yu, Jingwei</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202402</creationdate><title>Analysis on the therapeutic effect of Cangfu Daotan Decoction combined with drospirenone and ethinylestradiol tablets (II) on patients with polycystic ovary syndrome</title><author>Fu, Yanhong ; Xie, Pengpeng ; Yang, Qingping ; Chen, Peng ; Yu, Jingwei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c264t-b86d982266efc85066f851ce11e6bf1b38ede6a20524e53b5f2c5323afe7db683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Androstenes</topic><topic>Drugs, Chinese Herbal</topic><topic>Female</topic><topic>Humans</topic><topic>Insulin Resistance</topic><topic>Obesity</topic><topic>Polycystic Ovary Syndrome - drug therapy</topic><topic>Polycystic Ovary Syndrome - metabolism</topic><topic>Pregnancy</topic><topic>Tablets - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fu, Yanhong</creatorcontrib><creatorcontrib>Xie, Pengpeng</creatorcontrib><creatorcontrib>Yang, Qingping</creatorcontrib><creatorcontrib>Chen, Peng</creatorcontrib><creatorcontrib>Yu, Jingwei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Prostaglandins & other lipid mediators</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fu, Yanhong</au><au>Xie, Pengpeng</au><au>Yang, Qingping</au><au>Chen, Peng</au><au>Yu, Jingwei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Analysis on the therapeutic effect of Cangfu Daotan Decoction combined with drospirenone and ethinylestradiol tablets (II) on patients with polycystic ovary syndrome</atitle><jtitle>Prostaglandins & other lipid mediators</jtitle><addtitle>Prostaglandins Other Lipid Mediat</addtitle><date>2024-02</date><risdate>2024</risdate><volume>170</volume><spage>106801</spage><epage>106801</epage><pages>106801-106801</pages><artnum>106801</artnum><issn>1098-8823</issn><abstract>This study was designed to investigate the therapeutic effect of Cangfu Daotan Decoction (CDD) combined with drospirenone and ethinylestradiol tablets (II) on patients with polycystic ovary syndrome (PCOS).
Patients with PCOS were gathered from September 2020 to September 2022 and divided into the experimental group (n = 36), treated with CDD combined with drospirenone and ethinylestradiol tablets (II), and the control group (n = 41), received only drospirenone and ethinylestradiol tablets (II). Levels of sex hormone, obesity, blood glucose, blood lipid were detected and compared between the two groups pre- and post-treatment. The treatment efficacy, Traditional Chinese Medicine (TCM) syndrome score, adverse drug reactions, and pregnancy rate were compared as well.
After treatment, the experimental group had a higher treatment efficacy (94.44% vs 73.17%, P < 0.05) and a higher pregnancy rate (44.44% vs 21.95%, P < 0.05) than the control group, but the difference in the incidence of adverse drug reactions was not statistically significant (P > 0.05). Compared with control group, TCM syndrome score and levels of fasting blood glucose, fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR), and waist circumference of the experimental group after treatment displayed remarkable reduction (P < 0.05), while the levels of estradiol (E2) and high-density lipoprotein cholesterol (HDL-C) showed a remarkable increase (P < 0.05).
CDD in combination with drospirenone and ethinylestradiol tablets (II) may be effective in treating PCOS by improving obesity, glucose metabolism and lipid metabolism with no serious adverse events, making it a feasible clinical practice option.</abstract><cop>United States</cop><pmid>37984794</pmid><doi>10.1016/j.prostaglandins.2023.106801</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1098-8823 |
| ispartof | Prostaglandins & other lipid mediators, 2024-02, Vol.170, p.106801-106801, Article 106801 |
| issn | 1098-8823 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2892270872 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Androstenes Drugs, Chinese Herbal Female Humans Insulin Resistance Obesity Polycystic Ovary Syndrome - drug therapy Polycystic Ovary Syndrome - metabolism Pregnancy Tablets - therapeutic use |
| title | Analysis on the therapeutic effect of Cangfu Daotan Decoction combined with drospirenone and ethinylestradiol tablets (II) on patients with polycystic ovary syndrome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T09%3A17%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Analysis%20on%20the%20therapeutic%20effect%20of%20Cangfu%20Daotan%20Decoction%20combined%20with%20drospirenone%20and%20ethinylestradiol%20tablets%20(II)%20on%20patients%20with%20polycystic%20ovary%20syndrome&rft.jtitle=Prostaglandins%20&%20other%20lipid%20mediators&rft.au=Fu,%20Yanhong&rft.date=2024-02&rft.volume=170&rft.spage=106801&rft.epage=106801&rft.pages=106801-106801&rft.artnum=106801&rft.issn=1098-8823&rft_id=info:doi/10.1016/j.prostaglandins.2023.106801&rft_dat=%3Cproquest_cross%3E2892270872%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2892270872&rft_id=info:pmid/37984794&rfr_iscdi=true |